<DOC>
	<DOC>NCT00069706</DOC>
	<brief_summary>The purpose of this study is to determine the safety and IOP-lowering ability of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension.</brief_summary>
	<brief_title>Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>18 years or older. Diagnosis of openangle glaucoma or ocular hypertension. LogMAR visual acuity not worse than 0.6. Other protocoldefined inclusion criteria may apply. Clinically relevant ophthalmic or systemic conditions. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>open-angle</keyword>
	<keyword>glaucoma</keyword>
	<keyword>ocular</keyword>
	<keyword>hypertension</keyword>
	<keyword>POAG</keyword>
</DOC>